![John Mendelsohn, translational researcher who led MD Anderson for 15 years, dies at 82](https://cdn.cancerletter.com/media/2019/01/tennis-web.jpg)
![John Mendelsohn, translational researcher who led MD Anderson for 15 years, dies at 82](https://cdn.cancerletter.com/media/2019/01/tennis-web.jpg)
Cover Story
Free
John Mendelsohn, president emeritus of MD Anderson Cancer Center and an elder statesman in oncology, died Jan. 7 at his home in Houston. He was 82.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Funding Opportunities
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- Proposed rule by CMS would expand access to cancer treatment at tribal facilities
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence